Open Access

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)

  • Authors:
    • Chun Wei
    • Xiaojun Lan
    • Maona Qiu
    • Ran Cui
    • Qiuxia Fu
    • Shafiu A. Umar Shinge
    • Tobias Achu Muluh
    • Ou Jiang
  • View Affiliations

  • Published online on: July 17, 2023     https://doi.org/10.3892/ol.2023.13958
  • Article Number: 372
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunotherapy has become one of the most promising approaches in tumor therapy, and there are numerous associated clinical trials in China. As an immunosuppressive tumor, head and neck squamous cell carcinoma (HNSCC) carries a high mutation burden, making immune checkpoint inhibitors promising candidates in this field due to their unique mechanism of action. The present review outlines a comprehensive multidisciplinary cancer treatment approach and elaborates on how combining immunochemotherapy and immunoradiotherapy guidelines could enhance clinical efficacy in patients with HNSCC. Furthermore, the present review explores the immunology of HNSCC, current immunotherapeutic strategies to enhance antitumor activity, ongoing clinical trials and the future direction of the current immune landscape in HNSCC. Advanced‑stage HNSCC presents with a poor prognosis, low survival rates and minimal improvement in patient survival trends over time. Understanding the potential of immunotherapy and ways to combine it with surgery, chemotherapy and radiotherapy confers good prospects for the management of human papillomavirus (HPV)‑positive HNSCC, as well as other HPV‑positive malignancies. Understanding the immune system and its effect on HNSCC progression and metastasis will help to uncover novel biomarkers for the selection of patients and to enhance the efficacy of treatments. Further research on why current immune checkpoint inhibitors and targeted drugs are only effective for some patients in the clinic is needed; therefore, further research is required to improve the overall survival of affected patients.
View Figures
View References

Related Articles

Journal Cover

September-2023
Volume 26 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wei C, Lan X, Qiu M, Cui R, Fu Q, Umar Shinge SA, Muluh TA and Jiang O: Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review). Oncol Lett 26: 372, 2023.
APA
Wei, C., Lan, X., Qiu, M., Cui, R., Fu, Q., Umar Shinge, S.A. ... Jiang, O. (2023). Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review). Oncology Letters, 26, 372. https://doi.org/10.3892/ol.2023.13958
MLA
Wei, C., Lan, X., Qiu, M., Cui, R., Fu, Q., Umar Shinge, S. A., Muluh, T. A., Jiang, O."Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)". Oncology Letters 26.3 (2023): 372.
Chicago
Wei, C., Lan, X., Qiu, M., Cui, R., Fu, Q., Umar Shinge, S. A., Muluh, T. A., Jiang, O."Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)". Oncology Letters 26, no. 3 (2023): 372. https://doi.org/10.3892/ol.2023.13958